My only question: is it better to start a separate fund (OS fund) or company (Kernel) for biomedical research rather than joining a pre-existing one? The artic

My only question: is it better to start a separate fund (OS fund) or company (Kernel) for biomedical research rather than joining a pre-existing one? The article said that Pfizer annually spends $7-9bn on R&D. Maybe resources are spread too thin; people want moonshots in the biomedical industry as there were in tech, but barriers for entry in this field seem too high. The benefits are long-term, something I think private investment won't be interested in but perhaps private innovators will be.